AviadoBio

Publications and Presentations

Effective knockdown of ATXN2 following intracerebroventricular administration of AVB-205 construct in BAC-ATXN2-Q72 transgenic mice

Date: Dec 7, 2024

Conference / Journal: International Symposium on ALS/MND

Author(s): P.M. Coan

A Translational Assay for Ataxin-2 Related Drug Development Products

Date: Dec 7, 2024

Conference / Journal: International Symposium on ALS/MND

Author(s): B. Rougemont

Effective SOD1 targeting with vMiX™, an innovative AAV-based RNA interference platform

Date: Dec 7, 2024

Conference / Journal: International Symposium on ALS/MND

Author(s): L. Reilly

vMiX , an innovative AAV-based RNA interference platform: from in vitro development to in vivo validation by targeting genes involved in ALS

Date: Oct 24, 2024

Conference / Journal: ESGCT 2024

Author(s): R. Joubert

Effective SOD1 targeting with vMiXTM, an innovative AAV-based RNA interference platform

Date: Oct 23, 2024

Conference / Journal: ESGCT 2024

Author(s): L. Reilly

Development of an in vitro potency assay for AVB-101, a recombinant AAV9 gene therapy for the treatment of frontotemporal dementia with progranulin mutations

Date: Oct 23, 2024

Conference / Journal: ESGCT 2024

Author(s): R. Lyth

Development of a triplex one-step RT-ddPCR method as a quantitative potency assay for the vMiXTM platform

Date: Oct 23, 2024

Conference / Journal: ESGCT 2024

Author(s): R. Lyth

The vMiX™ platform: Tailored miRNA gene therapy targeting molecular drivers of ALS and FTD

Date: Oct 22, 2024

Conference / Journal: ESGCT 2024

Author(s): A. Ule

Effective knockdown of ATXN2 following intracerebroventricular administration of AVB-205 construct in BAC-ATXN2-Q72 transgenic mice

Date: Oct 22, 2024

Conference / Journal: ESGCT 2024

Author(s): P.M. Coan

Development of HPLC-based methods for the systematic quantification of multiple quality attributes of AAV9 preparations

Date: Oct 22, 2024

Conference / Journal: ESGCT 2024

Author(s): A. Martorana

Pre-Clinical Development of AVB-101, an AAV Gene Therapy Treatment for Frontotemporal Dementia with Progranulin Mutations

Date: Sep 21, 2024

Conference / Journal: ISFTD 2024

Author(s): Youn Bok Lee PhD

ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN Mutations: Study Update

Date: Sep 19, 2024

Conference / Journal: ISFTD 2024

Author(s): Jane Chan

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

SCIENCE & DELIVERY

Find out more about how we are progressing innovative gene therapies to potentially treat neurodegenerative disease. 

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

 

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here